Ami Kerr

Ami Kerr has a diverse work experience in the pharmaceutical industry. Ami is currently working as a Specialty Account Manager at Axsome Therapeutics, Inc. since June 2023. Prior to this, they worked as a Territory Business Manager at Alkermes from October 2021 to June 2023. Before that, they served as a Neuroscience Account Manager at Lundbeck from April 2020 to October 2021.

Ami also has experience working at Amgen as a Sr. Biopharmaceutical Representative from February 2017 to April 2020. Prior to that, they worked at AstraZeneca as a Sales Specialist from April 2015 to February 2017, where they were responsible for daily communication with various physicians across South Dakota, discussing products like Symbicort, Crestor, Tudorza, and Bevespi. Ami also worked at AstraZeneca as a Sales Specialist from August 2011 to March 2015, where their role included daily communication with physicians in parts of Minnesota, Iowa, and South Dakota, promoting products such as Vimovo, Symbicort, Crestor, Brilinta, and Farxiga.

Ami's earlier experience includes working at Eli Lilly and Company as a Senior Sales Representative from July 2008 to July 2011, where they introduced new medications to cardiologists and primary care physicians. Ami also worked at Eli Lilly and Company as a Senior Sales Representative from June 2004 to July 2008, where they communicated with psychiatrists and community mental health centers about products like Zyprexa, Cymbalta, Symbyax, and Strattera. Additionally, they worked as a Sales Representative at Eli Lilly and Company from August 2000 to June 2004, where they had regular communication with physicians about various products including Prozac, Sarafem, Evista, and Axid.

Ami's early career started as a Senior Accountant at Archer Daniels Midland from May 1998 to August 2000.

Ami Kerr attended the University of Illinois at Urbana-Champaign from 1994 to 1996, where they studied accounting. Ami then transferred to Millikin University and obtained a Bachelor's Degree in accounting, which they completed from 1996 to 1998.